AI Article Synopsis

  • Relapsing polychondritis (RP) is a rare multisystem disease that can severely affect the airway, potentially leading to fatal consequences for nearly half of those diagnosed.
  • Treatment options include immunotherapies and endobronchial stenting; however, stenting comes with its own risks and can increase overall complications.
  • A case study involving a 76-year-old man demonstrated that placing multiple stents in his left main bronchus significantly improved his breathing and daily activities, highlighting the importance of timely interventions for RP-related airway issues.

Article Abstract

Relapsing polychondritis (RP) is a rare multisystem condition. Nearly 50% of patients are suffering from airway involvement in RP and it can be fatal. Besides immunotherapies, endobronchial stenting has been found to be useful in the treatment. Insertion of endobronchial stents in patients with RP has it's own complications and has been associated with increasing morbidity and mortality. We describe placement of multiple endobronchial stents to prevent airway closure in a 76-year-old man with RP due to recurrent dyspnea. Insertion of multiple stents (6th stent) in the left main bronchus was necessary due to severe narrowing of the left main bronchus. Recurrence of airway involvement in RP is common. Early diagnosis and prompt treatment are essential to reduce the risk of life-threatening airway collapse. The insertion of multiple stents in this patient has resulted in improving symptoms, spirometry, and a return to daily activities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749233PMC
http://dx.doi.org/10.1016/j.rmcr.2022.101583DOI Listing

Publication Analysis

Top Keywords

multiple endobronchial
8
relapsing polychondritis
8
polychondritis rare
8
airway involvement
8
endobronchial stents
8
insertion multiple
8
multiple stents
8
left main
8
main bronchus
8
airway
5

Similar Publications

Tuberculosis (TB) is a great mimicker due to its various unusual and atypical presentations. Mass-like lesions in thoracic radiology may raise the suspicion of lung malignancy. A man in his early 50s complained of cough, low-grade fever and dyspnoea.

View Article and Find Full Text PDF

Radiological and Pathological Analysis of Pembrolizumab-Associated Lung Lesions: Diagnostic Challenges and Management.

Am J Case Rep

January 2025

Department of Pulmonary and Critical Care Medicine, Faculty and Graduate School of Medicine, Mie University, Tsu, Mie, Japan.

BACKGROUND Pembrolizumab, a programmed cell-death protein-1 (PD-1)-targeting antibody, extends survival in cancer patients but may cause lung injury as a side effect. This immunotherapy enhances the immune system's ability to recognize and eliminate cancer cells. However, its immunomodulatory action can sometimes lead to immune-related adverse events, including lung injury.

View Article and Find Full Text PDF

Introduction: The incidence of pulmonary imaging abnormalities continues to increase. While standard CP-EBUS is safe and accurate, it has limited reach through smaller bronchi. Olympus BF-Y0069 TCP-EBUS has smaller diameter and improved angulation.

View Article and Find Full Text PDF

Pulmonary blastoma (PB) is a rare and aggressive lung neoplasm, representing 0.25 %-0.50 % of lung cancers and characterized by biphasic histology with both epithelial and mesenchymal components.

View Article and Find Full Text PDF
Article Synopsis
  • * Diagnostic imaging confirmed the mass as a plasma cell tumor, and after a successful endoscopic surgery to remove it, the patient showed significant improvement and was discharged quickly.
  • * The report emphasizes the need for thorough diagnostic processes for patients with obstructive bronchial masses and suggests that early detection and treatment of plasmacytoma can lead to better patient outcomes, highlighting the importance of regular follow-ups to prevent recurrence.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!